Oncology Therapeutic Development
Oncology Therapeutic Development is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid tumors
Sponsor Merus B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer
Sponsor T.O.A.D. Oncology S.A.
- Start (EU)
- Latest update
- Estimated end
Actuate 1801: Phase 1/2 Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Sponsor Actuate Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Oncology Therapeutic Development?
The 2026-10-09 snapshot links Oncology Therapeutic Development to 3 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Regulatory services, Medical writing, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Oncology Therapeutic Development?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Oncology Therapeutic Development conducted?
The linked trials record locations in 6 countries, including Spain, France, Belgium, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Oncology Therapeutic Development delivered services.
What can this page tell me about Oncology Therapeutic Development's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Oncology Therapeutic Development. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Oncology Therapeutic Development